Maravai LifeSciences is appointing William Martin as CEO to succeed Caleb Hull.
Mr. Hull will help Mr. Martin transition to CEO and continue to serve as chair of the board of directors. Prior to his new role, Mr. Martin served as senior vice president of new business in the genomic medicine department at the Danaher Corp., according to the Oct. 3 Maravai news release.
"I am thrilled to be joining Maravai, a global leader in nucleic acid production and biologic safety testing, at this exciting time in the company's evolution. I want to commend Carl for his leadership and thank him and the board for their confidence in me," Mr. Martin said. "I look forward to leading the outstanding team at Maravai, as we seek to further advance the field and enable the development of drug therapies, diagnostics and novel vaccines."